Study shows no CV risk with Nesina/Vipidia for Type 2D

Results of the EXAMINE cardiovascular (CV) safety outcomes trial testing Nesina/Vipidia (alogliptin), from Takeda, show alogliptin does not increase CV risk in Type 2 Diabetes patients at high-risk for major adverse cardiac events (MACE) due to a recent Acute Coronary Syndrome (ACS). A total of 5,380 patients were randomly assigned and followed for a median of 18 months and up to 40 months. The primary endpoint occurred at similar rates in the alogliptin and placebo groups (11.3% vs. 11.8%).

The secondary composite endpoint of CV death, myocardial infarction, stroke and unstable angina with urgent revascularization showed no difference in rates on alogliptin versus placebo (12.7% vs. 13.4%). All-cause mortality occurred in 153 patients treated with alogliptin (5.7%) and 173 patients treated with placebo (6.5%). The data, published in the New England Journal of Medicine (NEJM) are also presented at the ESC Congress 2013. See: "Alogliptin in Type 2 Diabetes" W.B. White et al. N ENg J Med September 2, 2013 DOI: 10.1056/NEJMoa1305889